Protocol of a two arm randomised, multi-centre, 12-month controlled trial:evaluating the impact of a Cognitive Behavioural Therapy (CBT)-based intervention Supporting UPtake and Adherence to antiretrovirals (SUPA) in adults with HIV by Horne, Rob et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s12889-019-6893-z
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Horne, R., Glendenning, E., King, K., Chalder, T., Sabin, C. A., Walker, A. S., ... Cooper, V. (2019). Protocol of a
two arm randomised, multi-centre, 12-month controlled trial: evaluating the impact of a Cognitive Behavioural
Therapy (CBT)-based intervention Supporting UPtake and Adherence to antiretrovirals (SUPA) in adults with
HIV. BMC Public Health, 19(1), [905]. https://doi.org/10.1186/s12889-019-6893-z
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. Jul. 2020
1 
 
 
 
Title 1 
Protocol of a two arm randomised, multi-centre, 12-month controlled trial: Evaluating the impact of 2 
a Cognitive Behavioural Therapy (CBT)-based intervention Supporting UPtake and Adherence to 3 
antiretrovirals (SUPA) in adults with HIV 4 
 5 
Public title 6 
Evaluating the impact of a cognitive Behavioural Therapy (CBT)-based intervention supporting 7 
uptake and adherence to antiretroviral therapy for HIV  8 
 9 
Authors 10 
Horne R 11 
Glendinning E 12 
King K 13 
Chalder T 14 
Sabin C 15 
Walker, AS 16 
Campbell LJ 17 
Mosweu I 18 
Anderson J 19 
Collins S 20 
Jopling R 21 
McCrone P 22 
Leake Date H 23 
Michie S 24 
Nelson M 25 
Perry N 26 
Smith JA 27 
Sseruma W 28 
Cooper V 29 
On behalf of the SUPA Group 30 
 31 
Corresponding author 32 
Elizabeth Glendinning 33 
Centre for Behavioural Medicine, Department of Practice and Policy, UCL School of 34 
Pharmacy, Mezzanine Floor, Entrance A, BMA House, Tavistock Square, London, WC1H 9JP, UK 35 
Email: e.poliquin@ucl.ac.uk 36 
 37 
  38 
2 
 
 
 
Other author affiliation and contact details  39 
Rob Horne 40 
Centre for Behavioural Medicine, Department of Practice and Policy, UCL School of 41 
Pharmacy, Mezzanine Floor, Entrance A, BMA House, Tavistock Square, London, WC1H 9JP, UK 42 
Telephone: (0) 207 874 1293; Fax: +44 207 848 5769; Email: r.horne@ucl.ac.uk 43 
 44 
Kathryn King 45 
Centre for Behavioural Medicine, Department of Practice and Policy, UCL School of 46 
Pharmacy, Mezzanine Floor, Entrance A, BMA House, Tavistock Square, London, WC1H 9JP, UK 47 
Email: Kathryn.king@ucl.ac.uk 48 
 49 
Trudie Chalder  50 
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's 51 
College London, 16 De Crespigny Park, London, SE5 8AF UK 52 
Email: trudie.chalder@kcl.ac.uk 53 
 54 
Caroline Sabin 55 
Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, 56 
UCL, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK 57 
Email: c.sabin@ucl.ac.uk 58 
 59 
A Sarah Walker 60 
MRC Clinical Trials Unit at UCL, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, UK 61 
Email: rmjlasw@ucl.ac.uk 62 
 63 
Lucy J Campbell  64 
HIV Research Centre, King’s College London, London, SE5 9RJ, UK 65 
Email: Lucy.campbell@kcl.ac.uk 66 
 67 
Iris Mosweu 68 
Institute of Psychiatry at King's College London, Denmark Hill, London, SE5 8AF, UK 69 
Email: iris.mosweu@kcl.ac.uk 70 
 71 
Jane Anderson  72 
Centre for the Study of Sexual Health and HIV, Homerton University Hospital, London, E9 6RS, 73 
United Kingdom 74 
Email: janderson@nhs.net 75 
 76 
Simon Collins  77 
HIV i-Base, 107 The Maltings, 169 Tower Bridge Road, London, SE1 3LJ, UK 78 
3 
 
 
 
Email: simon.collins@i-base.org.uk 79 
 80 
Rebecca Jopling 81 
Centre for Behavioural Medicine, Department of Practice and Policy, UCL School of 82 
Pharmacy, Mezzanine Floor, Entrance A, BMA House, Tavistock Square, London, WC1H 9JP, UK 83 
Email: r.jopling@ucl.ac.uk 84 
 85 
Paul McCrone 86 
Institute of Psychiatry at King's College London, Denmark Hill, London, SE5 8AF, UK 87 
Email: paul.mccrone@kcl.ac.uk 88 
 89 
Heather Leake Date 90 
Departments of of Pharmacy and HIV Medicine, Brighton & Sussex University Hospitals NHS Trust, 91 
Brighton, BN2 5B, UK 92 
Email: heather.leakedate@nhs.net 93 
 94 
Susan Michie 95 
Department of Clinical, Educational and Health Psychology, UCL, 1-19 Torrington Place, London, WC1E 7HB UK 96 
Email: s.michie@ucl.ac.uk 97 
 98 
Mark Nelson  99 
Kobler Clinic, Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London, 100 
SW10 9NH, UK 101 
Email: Mark.Nelson@chelwest.nhs.uk 102 
 103 
Nicky Perry  104 
Brighton and Sussex University Hospitals NHS Trust, Brighton, BN2 5BE, UK 105 
Email: nicky.perry@bsuh.nhs.uk 106 
 107 
Jonathan A Smith 108 
Department of Psychological Sciences, Birkbeck, University of London, London, UK 109 
Email:  ja.smith@bbk.ac.uk> 110 
 111 
Winnie Sseruma 112 
UK-CAB, 107 The Maltings, 169 Tower Bridge Road, London, SE1 3LJ, UK 113 
Email: ssanyu.sseruma184@gmail.com 114 
 115 
Vanessa Cooper  116 
Centre for Behavioural Medicine, Department of Practice and Policy, UCL School of 117 
Pharmacy, Mezzanine Floor, Entrance A, BMA House, Tavistock Square, London, WC1H 9JP, UK  118 
4 
 
 
 
Email: vanessaleecooper@gmail.com  119 
5 
 
 
 
Abstract  120 
BACKGROUND 121 
Delay to start antiretroviral therapy (ART) and nonadherence compromise the health and wellbeing 122 
of people living with HIV (PLWH), raise the cost of care and increase risk of transmission to sexual 123 
partners. To date, interventions to improve adherence to ART have had limited success, perhaps 124 
because they have failed to systematically elicit and address both perceptual and practical barriers to 125 
adherence. The primary aim of this study is to determine the efficacy of the Supporting UPtake and 126 
Adherence (SUPA) intervention.  127 
METHODS 128 
This study comprises 2 phases. Phase 1 is an observational cohort study, in which PLWH who are ART 129 
naïve and recommended to take ART by their clinician complete a questionnaire assessing their beliefs 130 
about ART over 12 months. Phase 2 is a randomised controlled trial (RCT) nested within the 131 
observational cohort study to investigate the effectiveness of the SUPA intervention on adherence to 132 
ART. PLWH at risk of nonadherence (based on their beliefs about ART) will be recruited and 133 
randomised 1:1 to the intervention (SUPA intervention + usual care) and control (usual care) arms. 134 
The SUPA intervention involves 4 tailored treatment support sessions delivered by a Research Nurse 135 
utilising a collaborative Cognitive Behavioural Therapy (CBT) and Motivational Interviewing (MI) 136 
approach. Sessions are tailored to individual needs and preferences based on the individual patient’s 137 
perceptions and practical barriers to ART. An animation series and intervention manual have been 138 
developed to communicate a rationale for the personal necessity for ART and illustrate concerns and 139 
potential solutions. The primary outcome is adherence to ART measured using Medication Event 140 
Monitoring System (MEMS). 372 patients will be sufficient to detect a 15% difference in adherence 141 
with 80% power and an alpha of 0.05.  Costs will be compared between intervention and control 142 
groups. Costs will be combined with the primary outcome in cost-effectiveness analyses. Quality 143 
adjusted life-years (QALYs) will also be estimated over the follow-up period and used in the analyses. 144 
DISCUSSION 145 
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The findings will enable patients, healthcare providers and policy makers to make informed decisions 146 
about the value of the SUPA intervention. 147 
TRIAL REGISTRATION 148 
The trial was retrospectively registered 21/02/2014, ISRCTN 35514212. 149 
 150 
Keywords  151 
Adherence; engagement; antiretroviral therapy; HIV; randomised controlled trial; beliefs about 152 
medicines; perceptions; cognitive behavioural therapy; motivational interviewing 153 
  154 
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Background  155 
Antiretroviral therapy (ART) has resulted in near-normal life expectancy for many people living with 156 
HIV (PLWH) [1] and there is solid evidence that viral suppression in PLWH taking ART prevents sexual 157 
transmission of HIV [2]. In the UK, uptake of ART among people with diagnosed HIV attending 158 
healthcare services is generally high, but a significant number of PLWH are not on ART[1]. The number 159 
of people with diagnosed HIV who are not taking ART is likely to be an underestimate because not 160 
everyone who is prescribed ART actually receives or takes it[2]. Furthermore, several studies show 161 
that nonadherence to ART remains suboptimal: a meta-analysis of 84 studies across 20 different 162 
countries found the mean rate of ART adherence (defined as ≥90%) was 62%[3].  In a more recent UK 163 
study, 873 (32%) of 2704 people taking ART reported nonadherence[4]. Delay to start ART and 164 
nonadherence compromise the health and wellbeing of individual patients, raise the cost of care and 165 
impact on public health through increased risk of transmission[5, 6]. Adherence to effective treatment 166 
should not only improve physical health, but also psychological wellbeing by empowering patients to 167 
take an active role in managing their condition[7]. Interventions to increase adherence to medicines 168 
have had limited success and it is not clear which strategies are most effective. Systematic reviews of 169 
adherence interventions have reported variable findings[8-11]. The most recent comprehensive 170 
systematic review and meta-analysis of interventions to increase adherence to ART found that a 171 
variety of different types of interventions (e.g. interventions delivered via short message service 172 
(SMS), counselling and interventions delivered by a treatment supporter) were effective but effect 173 
sizes were generally small and the review did not specify specific intervention content or theoretical 174 
approaches that were effective[12].  175 
 176 
In order to address this, we developed the Supporting Uptake and Adherence to ART (SUPA) 177 
intervention. In line with the guidance of the Medical Research Council (MRC)[13], the intervention 178 
was informed by our preparatory research in which we explored and developed relevant theory. In 179 
our preliminary studies, ART nonadherence had multiple causes for a given individual, both intentional 180 
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and unintentional[14]. We subsequently identified the salient beliefs about medicines influencing 181 
adherence[14]. In studies across a range of illnesses and in different cultural contexts, adherence was 182 
consistently related to how patients judged their personal necessity for treatment relative to their 183 
concerns about potential adverse effects[15]. Studies conducted with PLWH demonstrated the utility 184 
of this Necessity Concerns Framework (NCF) for predicting ART uptake and adherence[16, 17].  185 
 186 
In addition to perceptual factors influencing adherence, the National Institute for Clinical Excellence 187 
(NICE) recommends addressing practical factors such as limitations in capacity and resources: the 188 
Perceptions and Practicalities Approach (PAPA)[18]. To date, few interventions have utilised this 189 
approach. One exception is a telephone-based medicines support intervention, where patients 190 
receiving the intervention had fewer doubts about necessity and fewer concerns, fewer medication 191 
problems and higher reported adherence than standard care controls[19]. 192 
 193 
The content of the SUPA intervention has been described in detail [20]. In summary, the SUPA 194 
intervention uses a Perceptions and Practicalities Approach (PAPA) to support uptake and adherence 195 
to ART. It comprises 3 key elements aiming to address factors related to the motivation to take 196 
treatment, elicit and help the patient overcome barriers to implementing the intention to take 197 
treatment and help them establish routines leading to habit formation:  198 
- Communicate a common-sense rationale for ART 199 
- Elicit and address specific Necessity beliefs and Concerns about ART 200 
- Identify and address practical barriers to ART uptake and adherence. 201 
This paper describes the protocol of a study to determine the efficacy of the SUPA intervention for 202 
increasing uptake and adherence to ART. 203 
 204 
Primary objective 205 
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- To investigate the impact of the SUPA intervention on adherence to ART 206 
Secondary objectives 207 
- To investigate the impact of the SUPA intervention on treatment outcomes, engagement with 208 
care and patient-reported outcomes 209 
- To assess how patients’ beliefs about ART change over time and how this may predict 210 
adherence and engagement in care 211 
- To assess the costs and cost effectiveness of providing the intervention in the short and long-212 
term.  213 
 214 
Methods 215 
Study design 216 
This study comprises 2 phases (Fig. 1). Phase 1 is an observational cohort study, in which PLWH who 217 
are ART naïve and recommended to take ART by their clinician complete a questionnaire assessing 218 
their beliefs about ART over a period of 12 months. Phase 2 is a randomised controlled trial (RCT) 219 
nested within the observational cohort study to investigate the effectiveness of the SUPA intervention 220 
on adherence to ART and to explore the intervention mechanism. PLWH who are at risk of 221 
nonadherence will be recruited and randomised 1:1 to the intervention and control arms. All 222 
participants will receive usual care which is provided to all NHS patients through clinical support from 223 
a multi-disciplinary healthcare team including the patient’s assigned HIV physician, nurses, 224 
pharmacists and other healthcare professionals, such as clinical psychologists, as required. In addition, 225 
participants in the intervention arm will receive the SUPA intervention.  226 
 227 
(FIGURE 1 ABOUT HERE) 228 
 229 
Setting 230 
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This study will be conducted in HIV clinics in National Health Service (NHS) hospitals across England: 231 
Kings College Hospital, Homerton University Hospital, Queen Elizabeth hospital (Woolwich), University 232 
Hospital Lewisham, North Middlesex University Hospital, St. George’s Hospital, University Hospitals 233 
Birmingham and Bradford Teaching Hospitals. The sites were selected on the basis of clinician-234 
reported issues with suboptimal appointment attendance post HIV diagnosis.  235 
 236 
Participants 237 
Inclusion and exclusion criteria 238 
Participant inclusion criteria (Phases 1 and 2): (1) patients aged 18 years or above; (2) diagnosed HIV 239 
infection; (3) no previous prescription of ART (except women who have previously been prescribed 240 
ART for prevention of transmission during pregnancy and subsequently discontinued, who are 241 
considered eligible); (4) clinical recommendation to initiate ART treatment according to 242 
contemporaneous British HIV Association (BHIVA) guidelines or as deemed appropriate by the 243 
patient’s clinician; (5) able to provide written informed consent and available for long-term follow-up. 244 
Participant exclusion criteria: (1) patients who do not speak English; (2) those who plan to leave the 245 
country in the next 12 months and hence will not be available for follow-up appointments or 246 
telephone follow-ups; (3) participants already enrolled in a trial or in any research study which 247 
encourages adherence (e.g. clinical trial of an investigational medical product); (4) lack of capacity to 248 
provide informed consent; (5) hospitalisation for a mental disorder in the past 2 years; (6) current 249 
suicidality or self-harm; (7) pervasive developmental disorder; (8) active substance 250 
misuse/dependence in last three months which in the opinion of the physician or investigator renders 251 
the patient unable to adhere to the study protocol; (9) patients who have previously started 252 
antiretroviral therapy and subsequently discontinued, except if they have previously taken ART for 253 
pregnancy; (10) psychiatric or addictive disorders which  in the opinion of the clinician or investigator 254 
could preclude obtaining informed consent.  255 
 256 
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Recruitment  257 
A two-stage enrolment process will be employed: Patients who meet the inclusion criteria will be 258 
informed about the study from their HIV doctor, and will subsequently be referred to the study team.  259 
All patients who meet the inclusion criteria will be invited to participate in the observational 260 
component of the study (Phase 1). Following informed consent, all participants will complete the 261 
Beliefs about Medicines Questionnaire-ART specific version (BMQ-ART). The clinician or Research 262 
Assistant (RA) will score the questionnaire immediately. If the score indicates that the participant is at 263 
high risk for nonadherence (ART-Necessity score ≤3 and/or ART-Concerns score ≥3), they will be 264 
provided with information by the study team and invited to consider taking part in Phase 2, the 265 
interventional trial component. Further written informed consent to take part in Phase 2 will be 266 
received after the patient has been given an opportunity to consider their participation in the study 267 
and discuss this with others if they wish. 268 
 269 
Confidentiality  270 
The study will conform to the Caldicott Principles and ethical and legal guidelines covering consent, 271 
confidentiality and storage of data. All data will be kept confidential in accordance with the Data 272 
Protection Act. All participants will be allocated a study identification number, so the participants will 273 
only be identifiable to study staff. De-identified data (no name, date of birth) will be stored in a 274 
password-protected database at the UCL School of Pharmacy for fifteen years. After that time the 275 
study register, Case Report Forms (CRFs), and consent forms will be destroyed making it impossible to 276 
link participants' names to identification numbers. The original copy of the consent form will be stored 277 
in the patient’s case notes and a copy of the consent form will be kept in the site file. 278 
 279 
Randomisation  280 
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If the participant consents to participate in Phase 2, they will be randomly allocated to one of the two 281 
trial arms (open randomisation; ratio 1:1) by the King’s Clinical Trials Unit (KCTU), King’s College 282 
London. The randomisation procedure will be a stratified block randomisation. Centres will be blocked 283 
to ensure that there are equal participants in each arm at each site. The randomisation schedule will 284 
be incorporated into a dedicated electronic database and kept securely within this electronic system, 285 
inaccessible to the enrolment location. Once an eligible participant has given written informed 286 
consent and completed the baseline assessment, the RA will log on to the randomisation system, enter 287 
the participant identification number and hospital, and will click on the ‘randomise’ function. The 288 
treatment allocation will appear immediately on screen and be communicated to the patient. The 289 
confirmation of treatment allocation details will be sent to the research team immediately. The RA 290 
will inform the participant’s HIV clinical team on the same day.  Movement from the observational 291 
cohort to the intervention trial or declining participation in the trial will be recorded on the central 292 
database. 293 
 294 
Control: Care as usual (CAU) 295 
All participants (intervention and control group) receive care as usual. Although this may vary slightly 296 
by clinic, this follows the same framework across all sites. 297 
- If the participant is starting ART, standard of care typically includes: 298 
- Discussion with a doctor about starting ART (including why, what is involved, the 299 
importance of adherence); 300 
- Consultation with a pharmacist at first prescription discussing the importance of 301 
adherence and potential side effects; 302 
- Collection of 2-4 weeks of medication and appointment with clinic nurse for safety bloods 303 
at 2-4 weeks;  304 
- Review with their HIV doctor at 1 month; 305 
- Routine clinic visits at 3 or 6 monthly intervals with a nurse and HIV doctor. 306 
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 307 
- If the participant is not starting ART: 308 
- 3 monthly consultation with HIV doctor, discussing readiness and beliefs about 309 
medication with a view to commencing ART; 310 
- 3 monthly monitoring bloods with nurse. 311 
 312 
Intervention: SUPA Intervention + Care as usual (CAU) 313 
The SUPA intervention has been described in detail in a separate publication[20]. Patients randomised 314 
to the intervention group will receive treatment initiation support within one month of enrolment 315 
into the intervention trial. This support will be in the form of 4 tailored treatment support sessions 316 
delivered by a Research Nurse (RN) utilising a collaborative Cognitive Behavioural Therapy (CBT) and 317 
Motivational Interviewing (MI) approach. The sessions will be conducted face-to-face (or by telephone 318 
if the patient prefers or cannot meet face to face) and will communicate a rationale for the personal 319 
necessity of medication, elicit and address concerns about medication and problem-solve potential 320 
practical barriers to adherence. Sessions will be tailored to individual needs and preferences, based 321 
on (1) the individual patient’s perceptions and practical barriers to ART identified using the BMQ-ART, 322 
and (2) salient issues arising during the sessions. An animation series and intervention manual have 323 
been developed as tools to communicate a rationale for the personal necessity of ART and illustrate 324 
concerns and potential solutions. The specific timing of the sessions will differ according to the 325 
patient’s specific needs and availability; however, the first two sessions will take place within one 326 
month of enrolment, and sessions 3 and 4 will provide additional support 3 and 6 months post 327 
randomisation. These appointments will be scheduled at the patient’s convenience.  328 
 329 
 330 
 331 
 332 
 333 
Assessment of intervention fidelity  334 
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If the patient consents to audio recording, the intervention sessions will be recorded on a 335 
dictaphone. As in previous intervention trials[21], a  scale will be developed to rate the recorded 336 
sessions according to a rating protocol.  Two trained raters working independently will score 337 
randomly selected intervention recordings (1 intervention session from 20% of participants). 338 
Differences in ratings will be identified, discussed and resolved through a process of consensus and 339 
conciliation. 340 
 341 
Participants who delay starting ART (both arms) 342 
If participants delay or decline ART when treatment is offered by their clinician, they will continue in 343 
the study. For the intervention group, sessions will focus on barriers to starting treatment, rather than 344 
ongoing support with adherence.  345 
 346 
Participant follow-up  347 
Phase 1 - Observational cohort study 348 
At baseline and at the participant’s routine clinic visits 3, 6, and 12 months post-baseline, the 349 
participant will complete the observational study questionnaires (Table 1). If the participant does not 350 
have 3-monthly appointments as standard care,  or are not attending clinical appointments, they will 351 
be asked to either schedule a research visit or complete the questionnaires over the phone with a 352 
member of the research team.  353 
 354 
Phase 2 – Randomised controlled trial  355 
For trial participants, the baseline visit includes enrolment, randomisation and completion of the trial 356 
study questionnaires (Table 2). For intervention participants, this includes their first intervention 357 
session.  Participants in the intervention arm will then be invited to attend additional study visits at 1, 358 
3, 6 and 12-months post-randomisation.  Participants in the control arm will be invited to attend 359 
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additional study visits at 3, 6 and 12 months post-randomisation (Fig 1). Expenses for study visits will 360 
be reimbursed (£10 per visit). 361 
 362 
Data collection 363 
Medication Event Monitoring System (MEMS)  364 
When a participant chooses to initiate treatment, the pharmacy in each site will dispense the 365 
participant’s prescription in bottles approved by the SUPA study for use with a Medication Event 366 
Monitoring System (MEMS) TrackCap. Site pharmacists will receive training by a designated RA in the 367 
use of MEMS caps, and how to explain the use of MEMS cap to participants. The RA will also explain 368 
to the participant how to use the MEMS bottle and cap. If the first dispensing of ART in a MEMS bottle 369 
does not coincide with a research visit, the RA will contact the participant via telephone to give any 370 
necessary further explanation on how to use the MEMS cap. Participants will be offered an instruction 371 
sheet which will be given at their research visit. All pharmacy refill data available for each participant 372 
from starting treatment up to an including their most recent clinic visit will be collected electronically. 373 
 374 
Self-report measures will be completed by the participant with the help of the RA (if desired) at each 375 
study visit. All medical data will be collected by the RA from available patient notes and lab results.  376 
Baseline data will be collected at the enrolment visit. Measures completed at each assessment are 377 
shown in Tables 1 and 2. 378 
 379 
Primary endpoint 380 
The proportion of months under follow-up where adherence is greater than or equal to 90% 381 
Adherence is defined by MEMS data. As the distribution of this variable is unknown, we will 382 
categorise the proportion of participants achieving ≥90% adherence as < vs ≥0.8 of the follow-up 383 
months. Essentially, this study assesses whether the participant has been ≥90% adherent for at least 384 
80% of their time spent in the trial. The 80% threshold to define a good outcome is based on the fact 385 
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that 4-6 weeks delay to ART initiation following a treatment recommendation is reasonable, and if 386 
followed by consistent ≥90% adherence to ART for the remainder of the trial (10 of the 12 months), 387 
the participant is likely to achieve and maintain viral load suppression.  To calculate each monthly 388 
adherence value, the percentage of adherence (according to MEMS) for each individual over each 389 
month of follow-up from randomisation will be calculated, treating every day off ART or not taking 390 
all prescribed ART doses (indicating either nonadherence or delayed treatment initiation) as 0% 391 
adherence.   392 
 393 
Secondary endpoints 394 
Clinical endpoints  395 
Treatment failure  396 
Treatment failure is defined as either failure to take up treatment or experiencing virological failure 397 
once taking treatment, namely:  398 
- Not starting treatment within 6 months of the treatment recommendation. 399 
- Not obtaining a viral load of <50 copies/ml 6 months after commencing ART, or following viral 400 
suppression to <50 copies/ml a viral load rebound to >400 copies/ml on one occasion (single 401 
values >50 copies/ml will be used rather than requiring confirmation because the number of 402 
viral load measurements during the one year follow-up are too few for confirmation to be 403 
possible). 404 
- Following viral suppression to <50 copies/ml, 2 consecutive viral loads >50 copies/ml. 405 
 406 
Disengagement from care at 12 months 407 
Disengagement is defined as missing one or more routinely scheduled visits, including visits either 408 
not attended and not rescheduled or rescheduled but not attended before the participant’s next 409 
routine appointment is due.  410 
 411 
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Rate of ART regimen switches through 12 months 412 
The total number of drug changes is calculated over the 12-month study period, including changing 413 
from one drug to another drug for any reason (excluding changes from 3TC to FTC and vice versa 414 
where these are simply due to changing a fixed dose combination tablet).  415 
 416 
Referral out of the intervention at 12 months  417 
This is defined as being referred out of the intervention for more specialist or intensive care (e.g. 418 
seeing a Psychiatrist or Clinical Psychologist for adherence issues). This information will be recorded 419 
in clinic notes and monitored by the research team. 420 
 421 
Patient-reported endpoints 422 
Changes in perceptions of ART between baseline and 12 months 423 
Perceptions of ART will be measured using the BMQ-ART [14, 16] which was adapted following 424 
preparatory work with the target populations[22] to include items on culturally-specific and practical 425 
barriers specific to ART.  The BMQ-ART includes 2 scales: the ART-Necessity scale and the ART-426 
Concerns scale. The ART-Necessity scale consists of 10 items which assess how patients perceive 427 
their personal need for ART for keeping their HIV under control, maintaining their health and 428 
preventing illness.  The ART-Concerns scale consists of 10 items measuring concerns about potential 429 
adverse effects of ART that have been identified in previous studies. These include fears about short- 430 
and long-term side effects, concerns about the timing of tablets and the disruptive effects of the ART 431 
regimen on daily life.  Participants are asked to rate the extent to which they agree with each item 432 
on a scale with possible responses ranging from strongly agree (scored 5) to strongly disagree 433 
(scored 1). A total score for each scale is computed by adding the scores for each scale item together 434 
and dividing by the number of items. This yields a mean score ranging from 1 to 5 for the necessity 435 
and concerns scales.  436 
 437 
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Depression and anxiety at 12 months 438 
The Hospital Anxiety and Depression Scale[23] will be used to measure anxiety and depression. This 439 
14-item measure was designed to detect the presence and severity of anxiety and depression among 440 
patients attending outpatient clinics without the possibility that scores would be contaminated by 441 
reporting of physical symptoms. Possible responses for each item ranged from 0 to 3, with each 442 
seven-item scale having a total possible score range of 0 to 21. Higher scores indicate greater anxiety 443 
or depression. Good psychometric properties of the HADS have been found in studies including 444 
medical outpatients[23, 24]. 445 
 446 
Health-related quality of life at 12 months 447 
The Euroqol-5D (EQ-5D-5L) is a self-completed measure of health-related quality of life (HRQoL),  448 
comprising  5 questions relating to dimensions of health: mobility, self-care, ability to undertake usual 449 
activities, pain/discomfort, and anxiety/depression[25]. Each dimension has 5 levels from ‘no 450 
problems’ (scored 1) to ‘extreme problems’ (scored 5). This results in a score on each dimension that 451 
can be combined to a 5-digit number describing the patient’s state of health. These health states will 452 
be combined with population weights to estimate individual utility scores ranging from 0 (worst 453 
health) to 1 (full health), required for generating quality-adjusted life years[26, 27]. The scale also 454 
includes a visual analogue scale (EQ-VAS) where the participant is required to indicate their level of 455 
health on a vertical scale with endpoints labelled ‘the best health you can imagine’ and ‘the worst 456 
health you can imagine’. This score (from 0-100) represents the patient’s judgement of their own 457 
health. 458 
 459 
Health and social service use at 12 months 460 
Health and social service utilisation will be collected at baseline and each follow-up using a modified 461 
version of the Client Service Receipt Inventory (CSRI)[28]. The CSRI is a widely used measure that can 462 
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be adapted to meet the needs of each study/context in which it is used. It captures retrospective 463 
data on accommodation, employment (and time off work), contacts with community health 464 
professionals (e.g. GPs, social workers), hospital care (emergency department, inpatient and 465 
outpatient), laboratory tests, medication (including ART), social care and informal care from family 466 
and friends (i.e. support without payment). The CSRI enquires about whether contacts had occurred, 467 
how many, and where appropriate, the duration.  468 
 469 
Symptoms attributed to having HIV and/or taking ART. 470 
Each participant’s experience of symptoms will be measured using the Symptoms Associated with 471 
HIV and ART Questionnaire (SAQ)[29]. The SAQ measure consists of 16 symptoms and a section 472 
where the participant is invited to add any symptoms that they are experiencing that are not listed. 473 
The participant answers by saying whether they experience each symptom or not (yes/no). Where 474 
the answer is ‘yes,’ the participant is asked to evaluate the severity of the symptom on a 5-point 475 
Likert-type scale with responses ranging from ‘very mild’ to ‘very severe.’ In addition, participants 476 
are asked to indicate whether they think the symptom is being caused by HIV, ART, both HIV and 477 
ART or neither. Scores will be generated for the total number of symptoms the participant is 478 
experiencing (possible range 0-16), the number of symptoms that the participant attributes to HIV 479 
(possible range 0-16), and the number of symptoms that the participant attributes to ART side 480 
effects (possible range 0-16).   481 
 482 
Illness perceptions 483 
The 9-item Brief Illness Perception Questionnaire (bIPQ)[30] will be used to assess participants’ 484 
cognitive and emotional illness perceptions. Participants are presented with statements about HIV 485 
such as ‘how much does your illness affect your life?’. Eight items measure participants’ perceptions 486 
of the timeline, consequences, controllability, emotional effects and understanding of their HIV on a 487 
scale of 0-10 with anchors relevant to each dimension, where higher scores indicate a greater 488 
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strength of belief in the particular dimension. The final item asks participants to specify the 3 most 489 
important factors that they believe caused their condition.  A total score will be calculated by 490 
reverse scoring 3 items and adding them to the total score of the remaining 5 items. A higher score 491 
reflects a more threatening view of the illness.  492 
 493 
Self-reported adherence 494 
Adherence to ART is measured using the Medication Adherence Report Scale-5 item version, (MARS-495 
5)[31] consisting of 5 statements about different ways in which the participant might take their 496 
medication e.g. ‘I forget to take my medicines,’ scored on a 5-point Likert-type scale, where 1=always 497 
and 5= never. The statements are introduced in a non-threatening manner in order to minimise social 498 
pressure to under-report nonadherence. Adherence is expressed as a continuous scale with possible 499 
scores ranging from 5-25 with higher scores indicating greater adherence. 500 
 501 
ART intrusiveness 502 
The ART Intrusiveness Scale[32] consists of 10 questions which assesses the frequency and 503 
magnitude that the participants’ medication interferes with different aspects of their lives.  This 504 
measure consists of 10 statements about ways in which the medication intrudes in their life, e.g. ‘My 505 
ART restricts my ability to travel’, scored for frequency on a 5-point Likert-type scale, where 1=never 506 
and 5= always, and magnitude of the intrusion also on a 5-point Likert-type scale, where 1=low 507 
interference and 5=high interference. The items are summed for both frequency and magnitude of 508 
intrusion and higher scores indicate greater intrusion. 509 
 510 
Readiness to initiate ART 511 
HIV Treatment Readiness Scale. Following a treatment offer, patients’ perceived readiness to initiate 512 
ART will be measured using a single item developed for this study “I feel ready to start antiretroviral 513 
medication“. The participant is asked to indicate the extent to which they agree or disagree with this 514 
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statement on a 5-point Likert-type scale with response anchors “not ready” and “very ready.” This 515 
item was created based on the ‘readiness ruler’ [33], a motivational interviewing technique used 516 
within the SUPA intervention.  517 
 518 
Knowledge about HIV treatment 519 
Patients’ knowledge about HIV treatment will be measured using 13 items from the HIV Treatment 520 
Knowledge Scale[34]. The original scale consists of 21 items assessing knowledge about HIV and its 521 
treatment, e.g. “HIV medications help the body’s immune system get stronger (CD4 increase)”. Eight 522 
items were removed either because they assessed knowledge about transmission rather than 523 
treatment, or because the topic had been measured in other study questionnaires. Participants are 524 
required to indicate whether they believe each statement is true or false or whether they do not 525 
know the answer.  A total score is calculated by summing the number of correct responses and 526 
dividing by the total number of scale items. This yields a percentage of correct responses, with 527 
higher scores indicating greater HIV treatment knowledge. 528 
 529 
Qualitative data 530 
A subset of at least 20 participants receiving the SUPA intervention will be interviewed by a RA within 531 
3 months of receiving the last intervention session. To avoid bias, the RA will be independent to the 532 
RN delivering the intervention. The interview schedule will explore participants’ perceptions of the 533 
intervention (e.g. overall impression, positive features, room for improvement, ease of 534 
comprehension, perceived effect on adherence and overall wellbeing). Transcripts will be subjected 535 
to thematic analysis.  536 
 537 
Sample size calculations  538 
Phase 1 - Observational cohort  539 
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Our risk assessment for nonadherence was based on the findings of a previous prospective study of 540 
beliefs and adherence among PLWH [17]. Phase 1 assesses whether the initial risk assessment is valid 541 
in the current sample. As such we will not aim to obtain a particular sample size, but rather recruit as 542 
many patients as possible (all eligible patients attending the clinic will be invited to Phase 1). 543 
 544 
Phase 2 – Trial  545 
Since this study uses a novel measure combining both uptake and adherence, there are no data to 546 
inform a sample size calculation. It is plausible that the distribution could be bimodal or highly 547 
skewed. As the proportion with 90% adherence will also be bounded by [0,1], standard sample size 548 
calculations based on the normal distribution would likely be inappropriate, even if a standard 549 
deviation could be hypothesised. This study therefore defines a good primary outcome as ≥80% of 550 
follow-up months with ≥90% adherence. Since the study selects for an at-risk group, we would 551 
expect a large difference between control and intervention groups, and a 15% difference between 552 
groups is considered clinically significant based on estimated intervention costs. Table 3 shows the 553 
number of participants needed in each arm to detect a 15% difference in adherence from a range of 554 
possible control group percentages with >=0.8 of follow-up months with ≥90% adherence (80% 555 
power, 2-sided alpha=0.05). We will therefore recruit 372 participants.  556 
 557 
Table 3 Sample size calculations for Phase 2 – trial 558 
Standard of care group 
% with >0.8 of follow-up 
months with ≥90% 
adherence 
Intervention group % 
with >0.8 of follow-up 
months with ≥90% 
adherence 
N per arm Total N 
35% 50% 183 366 
45% 60% 186 372 
23 
 
 
 
50% 65% 183 366 
60% 75% 165 330 
70% 85% 134 268 
 559 
Statistical methods and analysis 560 
The SUPA intervention is hypothesised to be superior to care as usual, and therefore the planned 561 
analysis is intention to treat, including all randomised participants, with all participants analysed 562 
according to the study group to which they were randomised regardless of subsequent treatment 563 
received. Primary analysis will include all randomised participants other than those randomised in 564 
error (defined as not intending to randomise the participant through e.g. miscommunication, rather 565 
than a participant or clinician decision once the allocation has been given). 566 
 567 
A per-protocol analysis will be carried out on the primary endpoint including all participants in the 568 
intervention group who attended all 4 (2+1+1) sessions. If the intention to treat and per-protocol 569 
analyses on the primary endpoint leads to inconsistent results, then per-protocol analysis will also be 570 
carried out on all the other endpoints. 571 
 572 
Continuous variables will be summarised by medians and IQRs or means and standard deviations as 573 
appropriate depending on the distribution, and compared between groups using ranksum tests or t-574 
tests respectively. Comparisons of change from baseline in continuous variables will adjust for any 575 
baseline imbalances using either quantile or normal linear regression (depending on the shape of the 576 
distribution).  577 
 578 
Categorical variables will be summarised by frequency tables, and compared between groups using 579 
chi-squared tests, unless any cell count is <5 or cell percentage is <5% in which case exact tests will be 580 
used. Binary variables will be summarised by percentages, using standard exact 95% CI for the risk 581 
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differences. Time-to-event variables will be summarised using Kaplan-Meier curves and average 582 
differences between randomised groups estimated using Cox models. Patients without the event 583 
recorded will be censored at their last clinic visit. Proportionality of hazards will be tested; where 584 
significant departures exist, varying differences between randomised groups over time will be 585 
estimated using flexible parametric models of Royston and Parmar.  Rate of treatment switching will 586 
be analysed using Poisson regression, including all changes to ART as events and the total time under 587 
follow-up through the earliest of 12 months or the last patient visit as the person-time at risk. Primary 588 
analysis will not stratify by clinical centre. 589 
 590 
Subgroup analyses 591 
Subgroup analyses will be performed to assess heterogeneity in differences between randomised 592 
groups for the primary endpoint according to gender, ethnicity, number of intervention sessions 593 
attended, early (treatment indicated at point of diagnosis) vs late diagnosis (treatment not indicated 594 
at point of diagnosis), starting for clinical need vs starting for treatment as prevention, baseline CD4 595 
count, and baseline BMQ scores - low Necessity vs high Concern vs both low Necessity and high 596 
Concern. Subgroup analyses will use logistic regression to model interactions between randomised 597 
group and the factors above. 598 
 599 
Health economic analyses 600 
Perspective 601 
The evaluation will primarily adopt a health and social care perspective as preferred by the National 602 
Institute for Health and Care Excellence (NICE) for decision-making, including both direct and 603 
indirect costs of low uptake and sub-optimal adherence. Other resources relevant to a wider societal 604 
perspective such as informal care and productivity loss (due to time off work) will be included in the 605 
secondary analyses.  606 
 607 
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Intervention costs will be estimated from information relating to staff time (research nurses) in 608 
delivering the SUPA intervention, including time spent training and actually delivering the 609 
intervention, and other non-staff costs (e.g. manual development and printing). The frequency and 610 
duration of health and social care service use data will be combined with appropriate unit costs to 611 
generate total care costs per patient. 612 
 613 
Costs will be compared between intervention and control groups. Bootstrapping methods will be used 614 
to produce confidence intervals around the cost differences to account for skewness often associated 615 
with the distribution of cost data.  Costs will be combined with the primary trial outcome in the form 616 
of cost-effectiveness analyses. However, as the primary outcome is not a clinical outcome and is 617 
condition specific, quality adjusted life-years (QALYs) estimated from the EQ-5D will be used to 618 
estimate cost-effectiveness. The use of QALYs and the EQ-5D in HIV is supported by previous work. If 619 
the intervention results in reduced costs and better outcomes then it will be defined as being 620 
‘dominant.’ However, supposing the costs are higher and outcomes are better, then incremental cost-621 
effectiveness ratios will be calculated to show the extra costs incurred to gain an extra level of 622 
outcome. Uncertainty around cost-effectiveness estimates will be explored using cost-effectiveness 623 
planes. The results will be further evaluated using cost-effectiveness acceptability curves. 624 
 625 
Determining the cost effectiveness of the long-term impact of the interventions 626 
Although we will measure costs, QALYs and the cost per QALY over the study period, this information 627 
will be limited because it would be expected that QALY gains would largely occur later in time. To 628 
address this issue a Markov model will be constructed to examine how patients might move from one 629 
health state to another over a longer period of time. Health states will be defined according to CD4 630 
counts or viral load. The probabilities of moving from one health state to another will be based on a 631 
review of the literature and from expert opinion. Assuming some degree of patient variation, the data 632 
collected in the trial will give information on EQ-5D utility scores and costs that are associated with 633 
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different CD4 ranges and where necessary this information will be supplemented by data from the 634 
literature. As well as allowing us to assess the long-term cost-effectiveness of the interventions, this 635 
approach will enable an estimation of the long-term cost associated with different levels of ART uptake 636 
and adherence. This will be of importance from a public health perspective in that it will illustrate the 637 
economic savings that might be made through interventions. Increased uptake and adherence may 638 
have further benefits if infections in others are reduced and we will explore the possibility of 639 
incorporating such externalities into the model. The time horizon used will depend on data availability, 640 
but is it expected that we will measure costs and outcomes over a 5- 10, and 15-year period. The 641 
results over the longer periods will by definition be more speculative. 642 
 643 
Internal feasibility review 644 
Baseline data from the first 40 randomised patients (and 1-month data for those randomised to the 645 
intervention arm) will be reviewed with the Programme Management Group (PMG) and Programme 646 
Steering Committee (PSC) at respective group meetings. The groups will assess: 647 
1. Feasibility of recruitment and retention, identifying barriers to recruitment/retention and 648 
problems in delivery.  649 
2. Acceptability of study measures (Control and Intervention arms). 650 
3. Acceptability of the intervention by patients (Intervention arm only). 651 
4. Capacity of trial and local site personnel, including capacity of clinics to accommodate 652 
research staff, determining whether trial centres are fulfilling their commitments (i.e. helping 653 
with the identification and introduction of patients), and determining where further staff is 654 
needed to recruit patients and/or to deliver the intervention. 655 
The findings of the feasibility review, along with participant feedback, will be used to make any 656 
necessary modifications to the conduct of the trial.  657 
 658 
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Adverse events  659 
Adverse events (AE) include any clinical change, disease or disorder experienced by the participant 660 
during their participation in the trial, whether or not considered related to participation in the trial. A 661 
Serious Adverse Event (SAE) will be defined according to usual clinical trial definitions. If the RA/RN is 662 
uncertain about whether the AE is an SAE, they will contact the centre Principal Investigator for their 663 
opinion. All SAEs must be reported by the RA/RN to the patient’s doctor (or doctor to the RA/RN), the 664 
centre Principal Investigator and the Trial Manager immediately. SAEs that are related to 665 
administration of any of the research procedures will be reported to the Sponsor and also sent to REC 666 
by the CI (or delegated individual) within 15 days of the CI becoming aware of the event.  667 
 668 
After an SAE, a decision will be made as to whether the participant should be withdrawn from the 669 
trial, or need an alteration in their standard care. Arrangements will be made by the RN for further 670 
assessment and management as necessary. One month after an SAE, the RA/RN will provide both the 671 
site Principal Investigator and Trial Manager with a follow-up report. If the SAE is not resolved, further 672 
monthly reports will be sent via the Trial Manager to the Independent Data Monitoring Committee 673 
(IDMC). The RA/RN will forward these reports to the Research Ethics Committee, Sponsor, and local 674 
Research and Development (R&D) office. 675 
 676 
Trial discontinuation 677 
 678 
If a member of the clinical care team or the RN feels that the intervention is detrimental (for example, 679 
causing distress), the patient can be referred out of the intervention. Referral to a more specialised 680 
professional should be carried out by the patient’s Clinician. Participants may discontinue from 681 
participation at any time, at the discretion of the Investigator. Specific reasons for discontinuing a 682 
participant from either study are: 683 
1. Withdrawal of informed consent. 684 
2. Development of exclusion criteria or other safety reasons during the study. 685 
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3. Incorrect enrolment or randomisation of the participant. 686 
 687 
Participation in other studies 688 
Participation in other studies may be permitted (for example, qualitative or questionnaire-based 689 
studies) with the prior consent of the PMG. Patients who are participating in a study which encourages 690 
adherence (i.e. clinical trial of an investigational medical product) will be excluded. 691 
 692 
Strategies to promote recruitment 693 
The following steps will be taken in order to achieve adequate participant enrolment 694 
1. An RA will attend multidisciplinary clinical meetings at each site in order to identify study 695 
eligible patients.  696 
2. Where possible a RA will be present at HIV clinics when ART-naïve patients have pre-booked 697 
appointments with a consultant and spoke with the consultant prior to the appointment in 698 
order to remind them of the patient’s eligibility for the trial. The RA will also attend 699 
emergency clinics in order to recruit patients attending clinics who are not on ART.  700 
3. Written information has been developed to inform patients about different types of 701 
research (e.g. observational studies and randomised controlled trials). This is intended to 702 
help patients to make an informed decision about whether to take part in each part of the 703 
study. 704 
Strategies to promote data completeness 705 
We will take the following steps in order to promote participant retention and complete follow-up: 706 
1. Attempt to make the research visit convenient for participants by booking research visits to 707 
correspond with their regular care visits. 708 
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2. Participants will be contacted by their preferred mode of contact ahead of their research 709 
appointments to remind them and confirm attendance. 710 
3. Participants will be offered the option of completing follow-up questionnaires by telephone. 711 
4. Contact details will be checked at each appointment. 712 
5. We will keep in touch with participants by sending a birthday card or text (provided the 713 
participant has consented to receive communication from us).  714 
If the participant is withdrawn at the request of the Researcher or Clinician, final follow-up data should 715 
be collected as soon as possible (if appropriate). If the participant wishes to fully withdraw from Phase 716 
1 or 2, the RA will contact the participant to ascertain the reason for withdrawal (although the patient 717 
does not have to give any reason), and ask whether they consent for previously collected data to be 718 
kept and analysed. The RA/RN will ensure that every effort is made to obtain any final follow up data 719 
(including MEMS caps). If the patient chooses to withdraw from attending the intervention only (not 720 
the trial), the RA should attempt to request permission to complete the further research follow-up 721 
visits (including keeping the MEMS caps) at the scheduled time points. 722 
 723 
Trial organisation and management 724 
This study is being organised by the UCL School of Pharmacy, and sponsored by Brighton and Sussex 725 
University Hospitals NHS Trust. It is funded and has been peer-reviewed by the National Institute for 726 
Health Research (NIHR).  Neither the sponsor nor the funding body were or will be involved in the 727 
study design, data collection, data analysis, interpretation of data, writing of the manuscript or the 728 
decision to submit the manuscript for publication.  729 
 730 
 731 
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The study has been given a favourable ethical opinion for conduct by the East of England–Essex 732 
Research Ethics Committee (13/EE/0235). It is overseen by the SUPA Trial Management Group 733 
(TMG), Programme Management Group (PMG), Independent Data Monitoring Committee (IDMC) 734 
and Programme Steering Committee (PSC). The trial was retrospectively registered with the ISRCTN 735 
(35514212) on 21/02/2014. Further details on the charter for each group can be found in Table 4. 736 
Ethics approvals  737 
Good Clinical Practice and in accordance with all applicable regulatory requirements including the 738 
Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, 739 
2006 and any subsequent amendments. Any modifications to the protocol will be agreed upon by the 740 
TMG and PMG, and approved by the REC.   741 
Trial status  742 
The trial opened to recruitment in February 2014 and recruitment closed in June 2017, with both 743 
Phase 1 and 2 patients in follow up. No data cleaning or analysis of the trial has been executed prior 744 
to submission of this manuscript. See Table 5 for protocol revision chronology. 745 
 746 
Table 5   Protocol version revision chronology 747 
Amendment Version Date 
n/a 1.1 Date: 29.08.2013 
Substantial amendment: 1 2.0 Date: 21.01.2014 
Substantial amendment: 2 3.0 Date: 16.02.2015 
Substantial amendment: 3 4.0 Date: 28.01.2016 
Substantial amendment: 4 4.1 Date: 30.08.2016 
 748 
Auditing trial conduct 749 
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Trial data inputed into the online database will be reviewed throughout the trial for accuracy and 750 
completeness by the programme manager(s) and a reviewer who has not been responsible for data 751 
collection. Recruitment figures from each site will be reviewed monthly by the programme 752 
manager(s) and supplied as a report quarterly to the Programme Management Group and monthly 753 
to site investigators, and the IDMC will review recruitment figures and data completeness annually. 754 
 755 
Ancillary and post-trial care 756 
Local approvals and indemnity will be sought by each participating centre through their local R&D 757 
department.  Details of local indemnity arrangements ca1n be obtained through each centre's NHS 758 
R&D department. 759 
 760 
Stopping guidelines 761 
The IDMC will review blinded interim analyses by the IDMC annually. If the committee feels that the 762 
arms are unbalanced and being in one group is detrimental, the IDMC will advise the PSC who will 763 
review the findings and decide whether or not the trial should be stopped. 764 
 765 
Dissemination policy  766 
Study findings will be disseminated through publication in peer-reviewed scientific journals, national 767 
and international conferences, HIV community publications and the NIHR Journals library. 768 
 769 
Discussion  770 
We have described the design of the Supporting Uptake and Adherence to ART (SUPA) trial, an 771 
observational cohort study with nested randomised controlled trial evaluating the effectiveness of a 772 
CBT-based intervention to increase uptake and adherence to ART by addressing perceptual and 773 
practical barriers.  774 
32 
 
 
 
 775 
The intervention is based on the Necessity Concerns Framework and aims to address both perceptual 776 
and practical barriers to adherence as recommended by NICE[18] and the latest BHIVA guidelines[7]. 777 
The intervention has been developed according to published guidelines for the development of 778 
complex interventions[13] and builds on preparatory research with PLWH showing that uptake and 779 
adherence to ART is driven by patients’ perceptions of their personal necessity for ART and concerns 780 
about adverse effects[16, 17]. To our knowledge, this is the first study to provide support at the time 781 
of a treatment recommendation to PLWH who may be at risk of delaying uptake or developing issues 782 
with adherence. This study targets individuals who may be considered as being hard to reach, and 783 
who are not usually represented in randomised trials. The study design allows the examination of 784 
process variables and the mechanism by which the intervention exerts its effect. The cost 785 
effectiveness analysis will enable health-care service providers to make informed decisions about the 786 
value of the intervention.  787 
 788 
While it was not possible to mask the allocation of participants to intervention or control groups, we 789 
have taken steps to reduce bias, including blinding of the statistical team to group allocation and 790 
ensuring that data is not collected or entered by those delivering the intervention. It possible that the 791 
primary outcome measure (MEMS) may impact on adherence as it serves as a reminder to participants 792 
that they are monitored. However, the impact of adherence monitoring alone is likely to be 793 
minimal[35]. Although participants are selected for risk of delay to initiate treatment and 794 
nonadherence using a screening tool (BMQ-ART), patients who decline to take part in the study may 795 
represent a different group who are more at risk of disengaging from care. However, these 796 
participants will be followed up in the observational cohort, therefore their virological outcomes can 797 
be compared with those of trial participants.  798 
 799 
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This is the first study to apply the perceptions and practicalities approach recommended by NICE [18] 800 
to the design of an intervention to increase uptake and adherence to ART.  It will provide information 801 
on the efficacy of the intervention as well as the mechanism by which the intervention exerts its effect. 802 
The findings will enable patients, healthcare providers and policy makers to make informed decisions 803 
about the value of the intervention. 804 
 805 
List of abbreviations 806 
AE Adverse events 
ART Antiretroviral therapy 
bIPQ Brief Illness Perception Questionnaire 
BMQ-ART Beliefs about Medicines Questionnaire - Antiretroviral therapy 
CBT Cognitive Behavioural Therapy 
CSRI Client Service Receipt Inventory 
EQ-VAS Euroqol Visual Analogue Scale 
Euroqol-5D EQ-5D-5L 
KCTU King’s Clinical Trials Unit 
MARS Medication Adherence Report Scale 
MEMS Medication Event Monitoring System 
MI Motivational Interviewing 
MRC Medical Research Council 
NHS National Health Service 
NICE National Institute for Clinical Excellence 
PAPA Perceptions and Practicalities Approach 
PLWH People living with HIV 
PMG Programme Management Group 
PSC Programme Steering Committee 
QALYs Quality Adjusted Life-Years 
R&D Research & Development 
RA Research Assistant 
RCT Randomised controlled trial 
REC Research Ethics Committee 
RN Research Nurse 
SAE Serious Adverse Event 
SAQ Symptoms Associated with HIV and ART Questionnaire 
SUPA Supporting Uptake and Adherence to ART 
TMG Trial Management Group 
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Figure Legends  
 
Figure 1 Adapted CONSORT diagram of the study 
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Table 1  Summary of data collection at each timepoint (Phase 1 – observational study) 
 Baseline 
(month 0) 
Month 3 Month 6 Month 12 
Inclusion/Exclusion criteria  X    
Statement of informed consent  X    
Age X    
Sex X    
Ethnicity X    
Country of birth X    
Years lived in the UK X    
Parents’ country of birth X    
Sexual orientation X    
Marital status X    
Children X    
Children living at home X    
Living with people other than family? X    
Highest level of education X    
Current employment status X    
Household income X    
Date of HIV diagnosis  X    
Country of diagnosis X    
Likely mode of transmission X    
Medical history (and changes to) X X X X 
Concomitant diagnoses X    
Has the patient been prescribed ARVs? X X X X 
Has the patient accepted their ARV treatment 
offer? 
X X X X 
Date of first prescription for ARVs X X X X 
Is the patient starting ARVs whilst being 
pregnant? 
X X X X 
(If pregnant) how long for?  (In weeks) X X X X 
Which antiretroviral(s) has/have been 
prescribed? 
X X X X 
How many doses per day? X X X X 
Time of doses e.g. 13:00 (24-hour clock) X X X X 
Purpose of concomitant medication X X X X 
Frequency of concomitant medication e.g. 
once daily 
X X X X 
Start date of concomitant medication X X X X 
Is the participant registered with a GP?  X    
GP aware of participant’s HIV status? X    
  
 
 Baseline 
(month 0) 
Month 3 Month 6 Month 12 
Disclosed HIV diagnosis to friend/relative 
(specify) 
X X X X 
Know other people who are HIV positive? (e.g. 
friend) 
X X X X 
Units of alcohol consumed per week? X X X X 
Ever been a smoker? X    
How often does the participant use illicit 
drugs? 
X X X X 
CD4 count X X X X 
Viral load X X X X 
Beliefs about Medicines Questionnaire (BMQ) X X X X 
 
 
  
  
 
 Table 2  Summary of data collection at each timepoint(Phase 2 – trial) 
 Baseline 
(month 0) 
Month 1 
(CBT only) 
Month 3 Month 6 Month 12 
Inclusion/Exclusion criteria  X     
Statement of informed consent  X     
Demographic data 
Age X     
Sex X     
Ethnicity X     
Country of birth X     
Years lived in the UK X     
Parents’ country of birth X     
Sexual orientation X     
Marital status X     
Children X     
Children living at home X     
Living with people other than family? X     
Highest level of education X     
Current employment status X     
Household income X     
Diagnosis 
Date of HIV diagnosis  X     
Country of diagnosis X     
Likely mode of transmission X     
Medical history (and changes to) X X X X X 
Concomitant diagnoses X     
Medications 
Has the patient been prescribed ART? X X X X X 
Has the patient accepted their treatment 
offer? 
X X X X X 
Date of first prescription for ART X X X X X 
Is the patient starting ART whilst being 
pregnant? 
X X X X X 
(If pregnant) how long for?  (In weeks) X X X X X 
Which antiretroviral(s) has/have been 
prescribed? 
X X X X X 
How many doses per day? X X X X X 
Time of doses e.g. 13:00 (24-hour clock) X X X X X 
Concomitant Medications 
Purpose of concomitant medication X  X X X 
  
 
 Baseline 
(month 0) 
Month 1 
(CBT only) 
Month 3 Month 6 Month 12 
Frequency of concomitant medication e.g. 
once daily 
X  X X X 
Start date of concomitant medication X  X X X 
General Practice 
Is the participant registered with a GP?  X     
GP aware of participant’s HIV status? X     
Social support 
Disclosed HIV diagnosis to friend/relative 
(specify) 
X X X X X 
Know other people who are HIV positive? 
(e.g. friend) 
X  X X X 
Alcohol and drug use 
Units of alcohol consumed per week? X  X X X 
Ever been a smoker? X     
How often does the participant use illicit 
drugs? 
X  X X X 
Laboratory data 
CD4 count X X X X X 
Viral load X X X X X 
Patient questionnaires 
Beliefs about Medicines Questionnaire (BMQ) X X X X X 
ART intrusiveness scale (HIS) X X X X X 
Brief Illness Perceptions questionnaire (bIPQ) X X X X X 
Medication Adherence Report Scale (MARS)   X X X 
Hospital Anxiety and Depression Scale (HADS) X X X X X 
Treatment readiness X X    
Treatment knowledge X X X X X 
EQ-5D X X X X X 
CSRI X  X X X 
Symptoms Attribution Questionnaire (SAQ) X X X X X 
Adherence (if started treatment) 
Medication Adherence Report Scale (score)  X X X X 
MEMS data (how many times opened?)  X X X X 
What proportion of tablets was taken? (%)  X X X X 
What proportion of tablets was taken on 
time? (%) 
 X X X X 
Intervention 
  
 
 Baseline 
(month 0) 
Month 1 
(CBT only) 
Month 3 Month 6 Month 12 
Did they read the materials in their own time?  X X X X 
How useful did they find the materials?  X X X X 
How much did the materials made sense?  X X X X 
How easy did they were materials to read?  X X X X 
How enjoyable did they find were the 
materials? 
 X X X X 
How satisfied were they with the treatment 
support programme overall? 
 X X X X 
Attendance of intervention services 
No. contacts to reschedule intervention 
appointment 
 X X X X 
ARV switches 
Did participant request to switch ARVs?  X X X X 
Did physician switch ARVs?   
X 
X X X 
 
  
  
 
Table 3   Trial organisation and management 
Group Contact details 
Sponsor Trial Sponsor: Brighton and Sussex University Hospitals NHS Trust 
Sponsor’s Reference: 13/117/HOR 
Contact name: Scott Harfield 
Address: Research & Development Directorate, Royal Sussex County Hospital, Eastern 
Road, Brighton, BN2 5BE 
Telephone: 01273 696955 ext. 3538  
E-mail: sponsorship.approvals@bsuh.nhs.uk 
 
 Main role Specific responsibilities 
Trial 
Management 
Group (TMG) 
(Chief  
investigator, 
Programme 
Managers) 
Responsible for the design 
and conduct of SUPA and 
day to day management of 
the trial 
-Study planning 
-Organisation of committee meetings 
-Provide annual report to funder 
-Provide accrual figures to each site 
-Budget administration and contractual issues with 
individual centres 
-Advice for lead site investigators 
-Ethics committee and R&D applications 
-Data verification 
-Randomisation 
-Organisation of data storage 
-Preparation of protocol and revisions to trial 
documents,  
-managing publication of study reports 
-Maintaining databases, randomising patients,  
-Ensuring complete and correct data 
-Preparing reports 
-Dealing with research governance 
 
Programme 
Management 
Group (PMG) 
 
Assisting in managing the 
trial, including the clinical 
and practical aspects 
 
 
 
-input into and comment on the protocol and all trial 
documents 
-develop strategies to address any issues with 
recruitment 
-provide clinical or other expert guidance on clinical and 
practical queries and interpretation of information 
recorded on CRFs 
-input into the meetings of the PSC and IDMC when 
appropriate (open sections only) 
-provide response for and consider the implications of 
any recommendations made by the IDMC and accepted 
by the PSC  
 
Programme 
Steering 
Committee (PSC) 
To act as the oversight body 
for this trial on behalf of the 
Sponsor/Funder 
 
-provide expert oversight of the programme 
-make decisions as to the future continuation (or 
otherwise) of the programme 
  
 
-receive letters of feedback from the IDMC and consider 
their recommendations  
-assess the impact and relevance of any accumulating 
external evidence  
-monitor recruitment and follow-up rates and review 
strategies from PMG to deal with problems 
-approve any amendments to the protocol, where 
appropriate 
-approve any proposals by the PMG concerning any 
change to the design of the programme, including 
additional substudies 
-approve / comment on the statistical analysis plan, 
publication policy, main programme manuscript 
-approve external or early internal requests for release 
of data 
 
Independent 
Data Monitoring 
Committee 
(IDMC) 
Safeguard the interests of 
participants, assess the 
safety and efficacy of the 
interventions during the 
trial, and monitor the 
overall conduct of the trial. 
It is independent from the 
Sponsor.  
 
 
-receive and review information on the progress and 
accruing data of this programme and provide advice on 
the conduct of the programme to the Programme 
Steering Committee (PSC) 
-inform the Chair of the PSC if, in their view the results 
are likely to convince a broad range of clinicians, 
including those supporting the programme and the 
general clinical community, that, on balance, one trial 
arm is clearly indicated  
-perform interim review of the programme’s progress 
including updated figures on recruitment, data quality, 
adherence to protocol treatment and follow-up, and 
main outcomes and safety data 
-monitor: evidence for treatment differences in the 
main efficacy outcome measures, evidence for 
treatment harm, recruitment figures and losses to 
follow-up,  compliance with the protocol, sample size 
assumptions, compliance with previous IDMC 
recommendations, data quality and completeness  
-assess the impact and relevance of external evidence 
-suggest additional data analyses if necessary 
-advise on protocol modifications proposed by 
investigators 
 
Lead Site 
Investigators 
Responsible for local site 
trial management 
In each participating centre a lead investigator (HIV 
consultant) will be identified, to be responsible for 
identification of patients, recruitment, data collection 
and completion of CRFs, along with follow up of study 
patients and adherence to study protocol at their local 
site. 
 
 
  
  
 
 
